TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05909202

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR
Description: Nature-based non-immersive VR program
Study: NCT05731375

Intervention type: DIAGNOSTIC_TEST
Intervention: 31-MRS at 7 Tesla (T)
Description: 31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.
Study: NCT05909202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active VR
Description: Nature-based immersive VR program
Study: NCT04820127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized care preceded by a standardized assessment
Description: * personalized intervention plan (PIP) proposed to the patient/caregiver dyad to correct potentially reversible causes of psycho-behavioral symptoms. This PIP will be re-evaluated and adapted at each visit by the nurse in close collaboration with the GP;~* PIP implementation will be based on a close follow-up during the 18 months follow-up coordinated by the nurse (3 memory consultation visits, 3 home visits (with the GP) and 6 phone calls). This follow up will be enhanced with the use of a web platform (allowing teleconsultation, tele-expertise and telemonitoring);~* specific training on psycho-behavioral symptoms for caregivers at baseline and during follow-up will be performed. On line training on psycho-behavioral symptoms management for GP will be available;
Study: NCT06163469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder instillation with Irrisept
Description: 9 months of bladder instillations (3 months of saline and 6 months of chlorohexidine gluconate)
Study: NCT05150860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: At-home COVID-19 testing
Description: At-home over-the-counter (OTC) COVID-19 testing kits provided to middle school students and staff

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Onsite COVID-19 testing
Description: Onsite COVID-19 testing for middle school students and staff
Study: NCT06072027

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cytology
Description: Conventional cytology will be performed in parallel with VISIOCYT cytology in order to compare the two results.
Study: NCT05679700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Taping
Description: Rigid taping was applied to stroke patients with knee hyperextension.
Study: NCT04835467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-modal OCT-FLIm
Description: Intracoronary imaging using dual-modal OCT-FLIm catheter
Study: NCT05450562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR444200
Description: Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR444200
Description: Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR444200
Description: Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: concentrate for solution for infusion Route of administration: intravenous (IV) infusion
Study: NCT06179654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative pelvic floor physical therapy
Description: Pelvic floor physical therapy to start before prostate surgery rather than after surgery.
Study: NCT06177795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-visit patient text messaging
Description: Patients will be sent text message reminders 4 days and 14 days after their primary care visit. The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling. The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-visit patient text messaging
Description: Patients will be sent text message reminders 4 days and 14 days after their primary care visit. The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling. The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default pended order
Description: A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default pended order
Description: A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default pended order
Description: A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High risk bidirectional post-visit text messaging
Description: High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component after their visit. This intervention will query the patient about common questions or concerns about breast cancer screening. The bi-directional text messaging intervention will provide additional educational materials based on patient response as well as information about resources to help navigate to screening.
Study: NCT02891746

Intervention type: OTHER
Intervention: non invasive sampling

Intervention type: OTHER
Intervention: non invasive sampling
Study: NCT05265013

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASP-1929 Photoimmunotherapy
Description: ASP-1929 640 mg/m\^2 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg every three weeks on days 1 and 22 of each 6-week cycle, 30 minute IV infusion
Study: NCT06135818

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IRISA-TB
Description: ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.
Study: NCT05846386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: moderate-intensity resistance training: three sessions per week for one month. Participants had been instructed to perform exercises at a 4:2:4 tempo; that is, four sets of concentric contraction, two sets of isometric hold, and four sets of eccentric contraction. Participants had been instructed to complete a single set until volitional fatigue or been instructed to stop by the physiotherapist when the technique falters

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: The exercise program consisted of ten minutes warm-up, 45 minutes of moderate aerobic exercises upper extremity aerobic bulk muscles training and arm ergometer and cool-down in five minutes, respectively. That was done as 3 sessions/week for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: The exercise program consisted of ten minutes warm-up, 45 minutes of moderate aerobic exercises upper extremity aerobic bulk muscles training and arm ergometer and cool-down in five minutes, respectively. That was done as 3 sessions/week for 4 weeks.
Study: NCT06504550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercises
Description: The patients in the Schroth exercise group will start their exercise program under physiotherapist supervision.Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.These exercises include spinal elongation, de-rotation, de-flexion, stretching, strengthening exercises to maintain vertebral alignment.The participants will be asked to combine these exercises with their daily living activities (ADLs).During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support.Exercises are progressed from lying, sitting, or standing positions and from most to least passive support per a review of the quality of the performance.Decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises will depend on the patient's improvement in exercise performance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Klapp Exercises
Description: The patients in the Klapp exercise group will be treated with supervised klapp exercises. Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.In each session, a sequence of 8 postures of Klapp Exercises will be carried out. Each posture will be maintained for 4-5 minutes with rest breaks when needed.Positions that will be held are: 1) Lateral crawl, 2) Horizontal sliding, 3) Crawl posture near the ground, 4) Bunny hopping, 5) Arm turn, 6) Big arch, 7) Lateral crawl near the ground, 8) Big curve
Study: NCT05922306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGylated recombinant human interferon alpha-2b injection
Description: Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated recombinant human interferon alpha-2b injection
Description: Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.
Study: NCT05729048

Intervention type: DEVICE
Intervention: Starling
Description: Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood.~The Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode.~This information is used to determine cardiac output. The Starling monitor also measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling monitor.
Study: NCT05132426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute.
Study: NCT05370768

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Mindfully Intervention
Description: Includes meditation and using meditation and mindfulness in everyday life and in parenting interactions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Mindfully Intervention
Description: Includes meditation and using meditation and mindfulness in everyday life and in parenting interactions.
Study: NCT06563284

Intervention type: OTHER
Intervention: AURORA Mobile App
Description: Enrolled subjects will be asked to download the app for free from their smartphone store.~Weekly/bi-weekly updates were collected, and therapy adherence was facilitated with timed alerts. Patients completed the EQ-5D-5L, PSQI, PHQ-9 and GAD-7 questionnaires every four months to track quality of life, sleep quality, depression and anxiety.
Study: NCT06557603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin cream
Description: \[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin cream
Description: \[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soolantra ® (Ivermectin) cream
Description: \[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soolantra ® (Ivermectin) cream
Description: \[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
Study: NCT06212076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG1094
Description: IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg
Study: NCT05714501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Millipede System
Description: Mechanical thrombectomy
Study: NCT04643379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Supplied by Merck \& Co.
Study: NCT04857671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A in saline water
Description: 100 Allergan units Botulinum toxin A in a total of 2 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 100 IU per 20 injections points.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin Type A in saline water
Description: 100 Allergan units Botulinum toxin A in a total of 2 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 100 IU per 20 injections points.
Study: NCT04643379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Supplied by Merck \& Co.
Study: NCT04857671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotone saline water
Description: 2ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 20 injections points

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotone saline water
Description: 2ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 20 injections points
Study: NCT04140344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Group
Description: The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
Study: NCT06463899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multi-perforated catheter
Description: After skin closure, cardiac surgeons place multi-perforated catheters aseptically.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic procedure
Description: opioid analgesia (PCA morphine in bolus mode alone or morphine titration if PCA not available), nefopam, non-steroidal anti-inflammatory drugs, ketamine, pregabalin and paracetamol
Study: NCT04643379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Commercially available

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression
Study: NCT05377424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consume 20mg of istradefylline
Description: Consume a single 20 mg istradefylline tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consume 20mg of istradefylline
Description: Consume a single 20 mg istradefylline tablet
Study: NCT05963750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: virtual reality
Study: NCT04435782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67896049
Description: Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
Study: NCT04785963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music with Suggestion
Description: A nonpharmacological, short-term treatment that poses minimal risk and places very limited burden on patients seems ideal for this population, and music with suggestions is one such treatment option.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Information
Description: The comparison condition of informational recordings about chronic pain are structured to account for non-specific effects of general time and attention and to evaluate whether the treatments of music alone, and music in combination with suggestion are effective in the reduction of pain intensity more than an appropriate control group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: The comparison condition of the music only is structured to account for the effect of music listening, and to evaluate whether the addition of suggestion optimizes its effectiveness in the reduction of pain intensity.
Study: NCT05948072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + Cetuximab
Description: Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX 6
Description: mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT06256224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab combined with CCRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CCRT
Description: CCRT includes cisplatin (40 mg/m2, once a week for 5 weeks), radiotherapy (45-50.4Gy/25-28Fx, 5 fractions a week, followed by brachytherapy 24-30Gy/3-5Fx)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: CCRT includes cisplatin (40 mg/m2, once a week for 5 weeks), radiotherapy (45-50.4Gy/25-28Fx, 5 fractions a week, followed by brachytherapy 24-30Gy/3-5Fx)